Cost analysis of new antibiotics against serious gram - infections used in intensive care units: cefiderocol vs meropenem/varbobactam

• At: Seville (Spain) (2022)
• Type: Poster
• Poster code: HPS-026
• By: DI NARDO, Giovanni Battista (UOC FARMACIA, ASL Frosinone, Italy)
• Co-author(s): Dr Giovanni Battista Di Nardo, Hospital Pharmacist
  Dr Noemi Pagnotta, UOC Farmacia
  Dr Fulvio Ferrante, UOC Farmacia
  
• Abstract:

  Background Information:Infections caused by Gram-resistant bacteria are one of the main causes of mortality in patients in intensive care units. Eradication of these germs has a serious economic impact on public health budget. Cefiderocol and the combination Meropenem/Vaborbactam are state-of-the-art antibiotics used to treat such infections in..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login